MedTrace Logo

A Study of Probiotics in Patients With Acute Ischemic Stroke

NCT07651332 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2026-06-17

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the effect of daily oral administration of the probiotic supplement OMNi-BiOTiC® SR-9 for 90 days, compared to placebo, on gut microbiome beta diversity in patients aged 60 years or older with acute ischemic stroke.

Conditions

Interventions

DIETARY_SUPPLEMENT

probiotic supplement OMNi-BiOTiC® SR-9

Each sachet contains approximately 7.5 × 10\^9 live bacteria. Administered orally twice daily.

OTHER

Matching Placebo

Identical in appearance, packaging, and administration method to the probiotic preparation, with no active ingredients.

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Principal Investigators

  • Xunming Ji, PhD, MD · Xuanwu Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-06-30
Completion
2027-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07651332 on ClinicalTrials.gov